Phaseline

Companies › DynamiCure Biotechnology

DynamiCure Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DCSZ11
Monoclonal antibody targeting CD93
CD93Phase 1Advanced or Metastatic Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05785754DCSZ11Phase 1Advanced or Metastatic Solid TumorsOncologyDec 2026

Targets

CD93 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.